Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for ...

Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology.

Japan has approved two stem cell-based therapies for treating Parkinson's disease and heart failure in a world first, through ...

On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the ...

Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients ...

Nina Bauer of FUJIFILM Cellular Dynamics shares insight on addressing challenges and supporting developers heading towards commercialization.

XCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem ...

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients ...

iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...

Japan has cleared two therapies that began with the same lab technique and ended in very different parts of the body. One is ...